PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-38.19%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.78%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-62.08%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-81.50%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-66.03%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-66.07%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-66.22%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.03%
Share change of 0.03% while 4997.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
141.51%
10Y revenue/share CAGR above 1.5x 4997.T's 41.11%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
89.48%
5Y revenue/share CAGR above 1.5x 4997.T's 52.52%. David Dodd would look for consistent product or market expansions fueling outperformance.
20.00%
3Y revenue/share CAGR at 75-90% of 4997.T's 24.19%. Bill Ackman would expect new product strategies to close the gap.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
127.76%
Net income/share CAGR 1.25-1.5x 4997.T's 100.64%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
207.10%
Below 50% of 4997.T's 770.98%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
130.41%
Below 50% of 4997.T's 1282.72%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
308.17%
10Y equity/share CAGR above 1.5x 4997.T's 58.66%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
53.44%
5Y equity/share CAGR above 1.5x 4997.T's 11.52%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
22.99%
3Y equity/share CAGR above 1.5x 4997.T's 12.21%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.10%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
9.51%
Inventory growth well above 4997.T's 18.07%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.40%
Negative asset growth while 4997.T invests at 0.09%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.44%
We have a declining book value while 4997.T shows 2.12%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-3.42%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-19.59%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-12.35%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.